SGP SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. (SGP) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.67 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +6.4% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About SpyGlass Pharma, Inc.
Schering-Plough Corporation and its subsidiaries are engaged in the discovery, development, manufacturing and marketing of pharmaceutical products worldwide. The company operates primarily in the prescription pharmaceutical marketplace. However, where appropriate, the company has sought regulatory approval to switch prescription products to over-the-counter status as a means of extending a product's life cycle.
Sector
Healthcare
Industry
Drug Delivery